Corrigendum to “Enhancement in site-specific delivery of carvacrol for potential treatment of infected wounds using infection responsive nanoparticles loaded into dissolving microneedles: A proof of concept study.” [Eur. J. Pharm. Biopharm. 147 (2020) 57–68, (S0939641119313190), (10.1016/j.ejpb.2019.12.008)]

The authors regret that an error occurred during the preparation of Fig. 2 in the originally published version of this article. The correct SEM images for CAR MN arrays is provided below. This correction does not affect the description, interpretation, or conclusions of the study. The authors apologise for any inconvenience caused.[Figure presented] Fig. 2. Digital pictures of dissolving MN arrays (19 × 19) taken with Leica EZ4D digital microscope; (a1, a2) CAR and CAR-PCL NPs-MN arrays, and (c1, c2) NR-PCL NPs-MN arrays, (b1, b2) SEM images of CAR and CAR-PCL NPs-MN arrays. To use as a control in dermatokinetic studies, free CAR loaded MN arrays were also fabricated using the same molds (19 × 19, conical) as for NPs loaded MN arrays. Various FDA approved commonly used pharmaceutical polymers were tested for their potential to be used as matrices in the formation of dissolving MN arrays loaded with a high content of CAR. Representative images along with brief comments about identified properties of all the formulations tested are provided in Table S2. The final formulation [2%w/w carvacrol: 1% w/w Tween® 80: 16% w/w PVA (31–50 K): 20% w/w PVP (29–32 K)] was found promising for the fabrication of fully formed needles with required mechanical strength. Images taken with digital microscope and SEM are given in (a, b).